Sarepta Therapeutics Inc
SRPT21.730USD
+0.790+3.77%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.14BValor de mercado
9.08P/L TTM
Mais detalhes de Sarepta Therapeutics Inc Empresa
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Informações da empresa
Código da empresaSRPT
Nome da EmpresaSarepta Therapeutics Inc
Data de listagemJun 04, 1997
Fundado em2013
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Número de funcionários1372
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 04
Endereço215 1st St Ste 415
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142-1213
Telefone16172744000
Sitehttps://www.sarepta.com/
Código da empresaSRPT
Data de listagemJun 04, 1997
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Por EmpresaUSD
Nome
Receita
Proporção
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.64B
86.11%
Rest of World
150.25M
7.90%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Distribuição de ações
Atualizado em: seg, 19 de mai
Atualizado em: seg, 19 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Investidores
Investidores
Proporção
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Tipos de investidores
Investidores
Proporção
Investment Advisor
42.91%
Investment Advisor/Hedge Fund
37.22%
Hedge Fund
9.45%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.10%
Pension Fund
1.10%
Sovereign Wealth Fund
1.09%
Venture Capital
0.33%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
1045
100.62M
102.55%
-5.73M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
2022Q4
996
84.01M
95.72%
-10.12M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital International Investors
8.70M
8.96%
+2.44M
+38.95%
Dec 31, 2024
The Vanguard Group, Inc.
9.07M
9.34%
+117.52K
+1.31%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.94M
9.21%
+162.26K
+1.85%
Dec 31, 2024
Capital Research Global Investors
5.93M
6.11%
+49.00
+0.00%
Feb 28, 2025
State Street Global Advisors (US)
4.07M
4.19%
-200.90K
-4.70%
Dec 31, 2024
Janus Henderson Investors
4.33M
4.46%
-30.19K
-0.69%
Dec 31, 2024
Barry (Richard J)
3.18M
3.28%
+2.38K
+0.07%
Mar 10, 2025
Avoro Capital Advisors LLC
2.56M
2.63%
--
--
Dec 31, 2024
Wellington Management Company, LLP
2.07M
2.13%
-657.84K
-24.13%
Dec 31, 2024
Farallon Capital Management, L.L.C.
2.87M
2.95%
+285.10K
+11.05%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Global X Genomics & Biotechnology ETF
2.35%
First Trust NYSE Arca Biotechnology Index Fund
2.26%
iShares Neuroscience and Healthcare ETF
1.65%
Tema Neuroscience and Mental Health ETF
1.2%
WisdomTree BioRevolution Fund
0.92%
Harbor Human Capital Factor Unconstrained ETF
0.87%
SPDR S&P Biotech ETF
0.82%
VanEck Biotech ETF
0.74%
Invesco S&P MidCap 400 Pure Growth ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção2.35%
First Trust NYSE Arca Biotechnology Index Fund
Proporção2.26%
iShares Neuroscience and Healthcare ETF
Proporção1.65%
Tema Neuroscience and Mental Health ETF
Proporção1.2%
WisdomTree BioRevolution Fund
Proporção0.92%
Harbor Human Capital Factor Unconstrained ETF
Proporção0.87%
SPDR S&P Biotech ETF
Proporção0.82%
VanEck Biotech ETF
Proporção0.74%
Invesco S&P MidCap 400 Pure Growth ETF
Proporção0.57%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.54%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
